Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zhejiang Bossan Out-Licenses Ex-China Rights for EGFR Drug to CBT Pharma

publication date: Nov 28, 2018

Zhejiang Bossan Pharma out-licensed global ex-China rights for its innovative novel epidermal growth factor receptor (EGFR) inhibitor to CBT Pharma of California. CBT plans to test two of its own candidates -- a c-Met inhibitor and an anti-PD1 antibody --  together with the Bossan EGFR inhibitor, which is currently in a Phase I China trial. CBT has already partnered China rights for the c-Met inhibitor to Beijing Pearl Biotech and the anti-PD1 antibody to Genor Biotech. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here